1,4,7-Triazacyclononane-N,N',N''-triacetate (TCTA), a new hexadentate ligand for divalent and trivalent metal ions. Crystal structures of [CrIII(TCTA)], [FeIII(TCTA)], and Na[CuII(TCTA)].bul.2NaBr.bul.8H2O

Study of Copper(II) Polyazamacrocyclic Complexes by Electronic Absorption Spectrophotometry and EPR Spectroscopy

“…Furthermore, even though there is a reported EPR study on the Cu II /DOTA system, [8] the effect of the pH on the EPR pattern of these macrocyclic complexes in aqueous solution was never investigated. The solid-state structures of Cu II complexes with NOTA, [9] NOTP, [10] DOTA, [11] and analogous tetraazamacrocyclic ligands, [12][13][14][15][16][17][18][19][20] have been obtained by X-ray diffractrometry.…”

[ 64 Cu-NOTA-8-Aoc-BBN(7-14)NH 2 ] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues

“…Previous studies have described the potential use of NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) as a bifunctional chelating agent for divalent copper (30,31). NOTA has the capacity to form stable complexes with Cu 2ϩ and a host of other divalent and trivalent metal centers (32,33) and therefore may help to produce conjugates that overcome demetallation and uptake of tracer in hepatic tissue. The overall neutral charge of the Cu 2ϩ -NOTA conjugate may do much to improve accumulation and retention of conjugate in normal kidney tissue as well.…”

Molecular Imaging of Breast Cancer Tissue via Site-Directed Radiopharmaceuticals

“…Recently, we have reported on the superior microPET imaging quality of NOTA bifunctional chelator over that of the DOTA using 64 Cu in a GRPR-positive human prostate cancer mouse model . Previous investigations have reported a highly stable complex consisting of NOTA and divalent copper (Kukis et al, 1993;Geraldes et al, 2000;Wieghardt et al, 1982). Also reported are biomolecules conjugated with NOTA and chelating 64 Cu.…”

“…Since the liver is the anatomical location of copper metabolism, the stability of the copper chelate in a 64 Cu-containing radiopharmaceutical under physiological conditions is very important (Wadas et al, 2007). Increasing the stability of copper complexes in vivo has been a major focus in the field of nuclear medicine for some time (Di Bartolo et al, 2001 andGasser et al, 2008;Kukis et al, 1993;Voss et al, 2007;Pippin et al, 1991;Geraldes et al, 2000;Wieghardt et al, 1982;van der Merwe et al, 1985;Soluri et al, 2003;Maina et al, 2005;Monstein et al, 2006;Sun & Chen, 2007) as the development of stable copper complexes will allow for a variety of copper-based diagnostic and therapeutic strategies. Recent work in the field of copper radiochemistry has produced very promising results.…”